Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

InMed Pharmaceuticals Inc. - Common Shares (NQ: INM )

4.590 -0.070 (-1.50%)
Streaming Delayed Price Updated: 3:59 PM EST, Dec 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about InMed Pharmaceuticals Inc. - Common Shares

< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >
BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces General Meeting Voting, Publication of Key Article on CBN as Possible Glaucoma Treatment
Via Investor Brand Network
InMed Pharmaceuticals' Study Marks First Phase 2 Trial to Evaluate Cannabinol for Disease Treatment
InMed Pharmaceuticals (NASDAQ: INM) recently released its Q1 2022 financial results along with a business update showing positive momentum across all of its programs. Following... 
Via Benzinga
InMed Pharmaceuticals’ (NASDAQ: INM) Study Marks First Phase 2 Trial to Evaluate Cannabinol for Disease Treatment
Via Investor Brand Network
BioMedNewsBreaks – InMed Pharmaceuticals Inc.’s (NASDAQ: INM) Study Marks First Phase 2 Trial to Evaluate Cannabinol as Therapeutic Option for Disease Treatment
Via Investor Brand Network
InMed Pharmaceuticals Targeting Potential Therapeutics Addressing Unmet Needs
InMed Pharmaceuticals (NASDAQ: INM) recently filed a Patent Cooperation Treaty (“PCT”) application, which specifies a rare cannabinoid (new to InMed’s portfolio... 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Advances Strategy Toward Potential Therapeutics for Diseases with High Unmet Needs
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Advances Strategy Toward Potential Therapeutics for Diseases with High Unmet Needs
Via CannabisNewsWire
Topics Intellectual Property
Exposures Intellectual Property
InMed Pharmaceuticals Releases Q1 2022 Financial Results, Business Update
InMed Pharmaceuticals released Q1 2022 financial results in which it reported a year-on-year increase in research and development expenses primarily due to increased activities... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 29, 2021
Upgrades According to Odeon Capital, the prior rating for Wells Fargo & Co (NYSE: 
Via Benzinga
InMed Pharmaceuticals Inc. (NASDAQ: INM) Releases Q1 2022 Financial Results, Business Update Showing Positive Momentum Across All Its Programs
Via Investor Brand Network
InMed Pharmaceuticals Inc. (NASDAQ: INM) Releases Q1 2022 Financial Results, Business Update Showing Positive Momentum Across All Its Programs
Via CannabisNewsWire
InMed Pharmaceuticals Announces Participation in Upcoming Cannabis Conference
InMed Pharmaceuticals (NASDAQ: INM), a leader in the development, manufacturing, and commercialization of rare cannabinoids, will be participating in the 4th annual Cowen Cannabis... 
Via Benzinga
Topics Cannabis
Exposures Cannabis
InvestorNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Participation in Upcoming Cannabis Conference
Via Investor Brand Network
Topics Cannabis
Exposures Cannabis
Welcome to the Party $INM! Competition or Compliment to $SNDL? — Cannabis Daily November 18, 2021
The Best Daily Overview Of The Cannabis Space South Dakota lawmakers recommend bill to legalize marijuana. New York ban... 
Via Benzinga
Topics Cannabis
Exposures Cannabis
54 Biggest Movers From Yesterday
Gainers Longeveron Inc. (NASDAQ: LGVN) shares climbed 135.3% to close at $6.87 on Thursday. Longeveron said the FDA granted rare pediatric disease designation for the company... 
Via Benzinga
Exposures Product Safety
44 Stocks Moving In Thursday's Mid-Day Session
Gainers Longeveron Inc. (NASDAQ: LGVN) jumped 157% to $7.51. Longeveron said the FDA granted rare pediatric disease designation for the company’s Lomecel-B for the... 
Via Benzinga
Exposures Product Safety
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Good morning, investor! We're getting right into the thick of it today with a look at the biggest pre-market stock movers for Thursday! 
Via InvestorPlace
24 Stocks Moving in Thursday's Pre-Market Session
Gainers Sono Group N.V. (NASDAQ: SEV) rose 33% to $50.80 in pre-market trading. Sono Group shares climbed 155% on Wednesday after the company priced its IPO at $15 per share.... 
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
InMed Pharmaceuticals Working to Address Rare Cannabinoid Opportunities
InMed Pharmaceuticals (NASDAQ: 
Via Benzinga
InMed Pharmaceuticals (INM): Progress Across the Business
LONDON, UK / ACCESSWIRE / November 17, 2021 / With the recent closing of the BayMedica acquisition, InMed now has a substantially different profile than just a few months ago. The company is now in its... 
From Edison Investment Research Limited
Via AccessWire
BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Working on Answer to Mass Production of Rare, Otherwise Depleted Cannabinoid Opportunities
Via Investor Brand Network
Topics Cannabis
Exposures Cannabis
InMed Pharmaceuticals Files Patent Application for Treatment of Neurodegenerative Diseases with Rare Cannabinoid
InMed Pharmaceuticals has filed an international patent application that specifies a rare cannabi... 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
InMed Pharmaceuticals Inc. (NASDAQ: INM) Files International Patent Application for Treating Neurodegenerative Diseases Using a New Rare Cannabinoid
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
InMed Pharmaceuticals Inc. (NASDAQ: INM) Files International Patent Application for Treating Neurodegenerative Diseases Using a New Rare Cannabinoid
Via CannabisNewsWire
Topics Intellectual Property
Exposures Intellectual Property
BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Releases Financial Results, Business Updates for Q1 2022
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
InMed Pharmaceuticals Inc. Files PCT Application for Treating Neurodegenerative Disease Using Rare Cannabinoid
InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing, development, and commercialization of rare cannabinoids, today announced its filing of an international patent... 
Via Benzinga
BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Files PCT Application for Treating Neurodegenerative Disease Using Rare Cannabinoid
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Successful Ginkgo Bioworks SPAC IPO Highlights Available Industry Opportunities
Special purpose acquisition company Soaring Eagle Acquisition Corp. combined with Ginkgo Bioworks to form publicly-listed Ginkgo Bioworks Holdings Inc., in what is the largest-... 
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
Successful Ginkgo Bioworks SPAC IPO Highlights Available Industry Opportunities for InMed Pharmaceuticals Inc. (NASDAQ: INM) and Synthetic Cannabinoid Production
Via Investor Brand Network
Topics Initial Public Offering
Exposures Securities Market
Successful Ginkgo Bioworks SPAC IPO Highlights Available Industry Opportunities for InMed Pharmaceuticals Inc. (NASDAQ: INM) and Synthetic Cannabinoid Production
Via CannabisNewsWire
Topics Initial Public Offering
Exposures Securities Market
< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.